Advances in Gastric and GE Junction Cancer Treatment: Durvalumab Combined with FLOT Shows Promising Results at ASCO
A groundbreaking phase 3 trial shows that combining durvalumab with FLOT chemotherapy significantly improves outcomes for patients with resectable gastric and GE junction cancer, offering new hope in cancer treatment.
Recent research presented at the American Society of Clinical Oncology (ASCO) meeting highlights a significant breakthrough in the treatment of resectable gastric and gastroesophageal (GE) junction adenocarcinoma. A phase 3, double-blind clinical trial investigated the efficacy of adding durvalumab, an immunotherapy drug, to the standard FLOT chemotherapy regimen.
The study involved 948 patients who were randomly assigned to receive either durvalumab (1,500 mg) or a placebo every four weeks. The treatment plan included four cycles of the combined therapy followed by 10 additional cycles of durvalumab or placebo. The primary focus was to assess event-free survival, which measures the length of time patients remain free from disease progression or recurrence.
Findings demonstrated that patients receiving durvalumab experienced notably better outcomes. The two-year event-free survival rate was 67.4% in the durvalumab group compared to 58.5% in the placebo group. Overall survival also improved, with 75.7% of durvalumab-treated patients surviving at two years versus 70.4% in the control group. Additionally, a higher proportion of patients in the durvalumab group achieved a pathological complete response (19.2% vs. 7.2%), indicating an absence of detectable cancer after treatment.
Dr. Yelena Y. Janjigian of Memorial Sloan Kettering Cancer Center emphasized the importance of these findings, stating that this therapy combination could represent a major advancement for patients facing this challenging diagnosis. The results suggest that adding durvalumab to the FLOT regimen could significantly enhance patient outcomes, bringing hope for higher cure rates.
The study was sponsored by AstraZeneca, which manufactures durvalumab. Several authors disclosed ties to pharmaceutical companies, aligned with the industry-led nature of the research.
For more on this study, visit the published article in the New England Journal of Medicine and the ASCO annual meeting resources.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Rise in Childhood Contact Allergies Over Two Decades
A recent study reveals a significant rise in contact allergies among children in Finland over the last 20 years, driven by increased exposure to cosmetics and adhesives. Early cosmetic use may lead to persistent skin allergies, emphasizing the need for awareness and preventive measures.
Socioeconomic Factors and Racial Disparities Influence Emergency Department Visits for Seizures
Socioeconomic status and racial disparities significantly influence emergency department visits among patients with seizures, highlighting systemic healthcare challenges.
Measles Outbreak in Rural Canadian Town Highlights Vaccine Hesitancy and Community Divisions
An outbreak of measles in a rural Canadian town reveals deepening vaccine skepticism and community divisions, threatening public health gains. Learn more about this growing concern.
FDA Moves to Ban Artificial Orange Food Dye B from U.S. Market
The FDA plans to ban Orange B, an artificial food dye unused for decades, citing outdated regulations and health concerns. This move is part of a wider effort to review and remove potentially harmful synthetic dyes from the U.S. food supply.